Psychometric properties of the abbreviated version of the Scale to Assess Unawareness in Mental Disorder in schizophrenia

Michel, Pierre; Baumstarck, Karine; Auquier, Pascal; Amador, Xavier; Dumas, R.; Fernandez, Jessica; Lançon, Christophe; Boyer, Laurent

doi:10.1186/1471-244x-13-229

Cited by 53 publications

(36 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…31 Poor insight into their disease process occurs in 30-50% of people with schizophrenia and is related to suboptimal outcomes. [32][33][34] In fact, studies of adherence to AP medication found that poor insight among people with schizophrenia is the best predictor of nonadherence. 32 A quality relationship between the person with schizophrenia and their health-care provider ( Fig.…”

Section: Person-centred Approachmentioning

confidence: 99%

Clinical benefits and impact of early use of long‐acting injectable antipsychotics for schizophrenia

Stevens

Dawson²,

Zummo

2015

Early Intervention Psych

View full text Add to dashboard Cite

AimResults from clinical trials support the use of oral antipsychotics for treatment of early or first‐episode psychosis in patients with schizophrenia. This paper will review literature on the advantages of early initiation of treatment for schizophrenia and the clinical benefits of early use of long‐acting injectable antipsychotics (LAIs).MethodA comprehensive literature review was conducted to identify published literature on the use of LAIs early in the treatment of schizophrenia.ResultsAlthough there is a higher response rate to initial antipsychotic treatment for a first‐episode of schizophrenia than with subsequent antipsychotic treatment, we have not effectively addressed this issue. Poor adherence to treatment is a primary cause of relapse and rehospitalization in subsequent years and was associated with higher relapse rates resulting in devastating effects and substantial economic burden. The costs of nonadherence were estimated to be $1.48 billion. Thus, a major challenge with the treatment of schizophrenia is changing poor adherence to persistence with antipsychotic therapy. LAIs are known to be at least as effective as oral antipsychotics for treating schizophrenia, and yet are underutilized. Further, LAIs address many of the problems associated with adherence to oral therapy. Recent evidence suggests that LAIs are effective for treating first‐episode psychosis and for early initiation of treatment for schizophrenia.ConclusionAlthough consistent antipsychotic treatment represents a critical part of treatment, a person‐centred approach to treating schizophrenia is essential for all aspects of care, including establishing and maintaining a therapeutic alliance, strengthening shared decision‐making and adherence, and achieving long‐lasting recovery.

show abstract

Section: Person-centred Approachmentioning

confidence: 99%

Clinical benefits and impact of early use of long‐acting injectable antipsychotics for schizophrenia

Stevens

Dawson²,

Zummo

2015

Early Intervention Psych

View full text Add to dashboard Cite

show abstract

“…Furthermore, it is not possible to determine a causal direction for the observed relationship between change in insight and improvement in negative and disorganized symptoms, as it is possible that symptom improvements led to improvements in insight In addition, our measure of insight consisted of a single item on the PANSS, rather than multidimensional measure of insight. Although, the PANSS insight item has been found to be strongly correlated with multidimensional measures of insight 24 , more nuanced measures of insight are preferable.…”

Section: Discussionmentioning

confidence: 99%

Insight among people with severe mental illness, co-occurring PTSD and elevated psychotic symptoms: Correlates and relationship to treatment participation

Yanos

Vayshenker

Pleskach

et al. 2016

Comprehensive Psychiatry

View full text Add to dashboard Cite

Background There is a dearth of research on what factors are predictive of insight among people with severe mental illness and co-occurring PTSD. Method Data were drawn from 146 participants with severe mental illness, co-occurring PTSD and elevated psychotic symptoms participating in a randomized controlled trial comparing two interventions for PTSD among people with severe mental illness. We examined the clinical and demographic correlates of insight at baseline, the relationship between baseline insight and treatment participation, the relationship between treatment participation and post-treatment insight, and the relationship between change in insight and change in other clinical variables. Results Impaired insight was relatively common, with roughly half the sample demonstrating mild or moderate impairment at baseline. Baseline insight was associated with fewer psychotic and disorganized symptoms, and greater emotional discomfort and PTSD knowledge, but was not associated with negative symptoms, PTSD symptoms, depression/anxiety, or treatment participation. Participation in PTSD treatment was associated with increased insight at post-treatment. Improved insight was associated with improvements in disorganization and negative symptoms, but not with knowledge of PTSD or positive symptoms. Discussion The findings suggest that engagement in treatment that includes educating people about PTSD may lead to improvements in insight and related improvements in other psychiatric symptoms.

show abstract

“…This version has shown good reliability and validity. It comprises three items for general awareness, three items for positive and three items for negative symptoms 8 . Self-stigma was assessed with the Internalized Stigma of Mental Illness (ISMI).…”

Section: Methodsmentioning

confidence: 99%

Insight and Self-Stigma in Patients With Schizophrenia

Vidović¹

2016

ACC

View full text Add to dashboard Cite

SUMMARY -Poor insight and high level of self-stigma are often present among patients with schizophrenia and are related to poorer treatment adherence, poorer social function and rehabilitation, aggressive behavior, higher level of depression, social anxiety, lower quality of life and selfesteem. Reports on a relationship between insight and stigma are controversial. We examined the relationship of the level of insight and self-stigma in a sample of 149 patients with schizophrenia. Insight was measured with the Scale to assess Unawareness of Mental Disorder and self-stigma with the Internalized Stigma of Mental Illness. Results showed 88.6% of the patients to have high or moderate insight, with a mean value of 2.73. General insight showed the highest level (2.58) and insight in positive symptoms the lowest level (2.9). The self-stigma score in general was 2.13, with stereotype endorsement being lowest (1.98). According to study results, 77.1% of patients felt minimal or low self-stigma across all subscales, except for stigma resistance subscale. Statistically significant correlation was found between insight and four subscales of self-stigma, while no correlation was found for the stigma resistance subscale only. These results imply the need of individually tailored antistigma and insight promoting programs for patients with schizophrenia.

show abstract

Psychometric properties of the abbreviated version of the Scale to Assess Unawareness in Mental Disorder in schizophrenia

Cited by 53 publications

References 62 publications

Clinical benefits and impact of early use of long‐acting injectable antipsychotics for schizophrenia

Clinical benefits and impact of early use of long‐acting injectable antipsychotics for schizophrenia

Insight among people with severe mental illness, co-occurring PTSD and elevated psychotic symptoms: Correlates and relationship to treatment participation

Insight and Self-Stigma in Patients With Schizophrenia

Contact Info

Product

Resources

About